The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for ...

This study is committed to searching for inhibitors of deacetylase SIRT2 within the natural product database via computer-aided drug design techniques. A comprehensive computer-aided drug design ...

The first patient has been enrolled in a Phase 1 trial by the NHLBI that's evaluating fostamatinib as a treatment for sickle ...

Naproxcinod [(S)-2-(6-Methoxy-2-naphthyl)propanoic acid 4-nitrooxybutyl ester], that is, NO-naproxen, is the first of the class of cyclooxygenase-inhibiting NO donators, and is currently in Phase ...

Background Cangrelor, an intravenous P2Y12-receptor inhibitor, is a reversible and short-acting antithrombotic medication non-inferior to irreversible glycoprotein IIb/IIIa inhibitors (GPIs) like ...

Human platelet lysates (HPL) are abundant in bioactive factors, and numerous studies have demonstrated their beneficial effects on neurological diseases, including their anti-neuroinflammatory ability ...

IPA: Inhibition of platelet aggregation ... The combined use of antiplatelet drugs acting through different mechanisms is important in antithrombotic treatment of patients with cardiovascular ...